1 Lu CH,Chen IH,Chen YJ,et al.Primary treatment and prognostic factors of carcinosarcoma of the ovary,fallopian tube,and peritoneum:a Taiwanese Gynecologic Oncology Group Study[J].Int J Gynecol Cancer,2014,24(3):506-512. 2 Pacaut C,Bourmaud A,Rivoirard R,et al.Uterine and ovary carcinosarcomas:outcome,prognosis factors,and adjuvant therapy[J].Am J Clin Oncol,2013,38(3):272-277. 3 Liu L,Yu H,Huang L,et al.Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer[J].Onco Targets Ther,2015,8:921-928. 4 Qin S.Phase Ⅲ study of Apatinib in advanced gastric cancer:A randomized double-blind,placebo-controlled trial[J].J Clin Oncol,2014,32(15 Suppl):a4003. 5 李旭,张翠翠,谭红叶,等.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果观察[J].中国生化药物杂志,2016,36(2):91-93. 6 Sawada M,Tsuda H,Kimura M,et al.Different expression patterns of KIT,EGFR,and HER2(c-erbB-2)oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma[J].Cancer Science,2003,94(11):986-991. 7 Folkman J.A Phase 3 Trial of Bevacizumab in ovarian cancer[J].N Engl J Med,2011,365(26):2484-2496. 8 Nishikawa T,Hasegawa K,Yabuno A,et al.Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma:a single institutional study[J].J Gynecol Oncol,2017,28(1):e25. |